A Study Utilising Data From European Union (EU) National Multiple Sclerosis (MS) Registries to Assess the Incidence of Anti-Natalizumab Antibody Among Participants Who Receive Subcutaneous Administration of Natalizumab for Treatment of Relapsing-remitting Multiple Sclerosis (RRMS)
Clinical trial NCT05925049 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05925049
- Sponsor
- Biogen
- Status
- ACTIVE_NOT_RECRUITING
- Study type
- OBSERVATIONAL
- Start date
- 2023-06-30
- Primary completion
- 2026-10-31
- Enrollment
- 400
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.